Yayıncı "Elsevier Science" Bildiri Koleksiyonu için listeleme
Toplam kayıt 9, listelenen: 1-9
-
Are pretreatment inflammation-based prognostic scores useful in predicting the outcomes of patients with ALK-positive NSCLC?
(Elsevier Science, 2019)Background: Approximately 5% of all diagnosed non-small cell lung cancer (NSCLC) patients harbor a genetic rearrangement between the ALK and EML4 genes, representing a specific molecular and clinical subgroup (ALK+ NSCLC). ... -
Clinicopathological factors in non-small cell lung cancer patients with bone metastases
(Elsevier Science, 2015)… -
Cost-effectiveness of sorafenib for treatment of radioactive iodine (rai)-refractory locally advanced/metastatic differentiated thyroid cancer (dtc) in Turkey
(Elsevier Science, 2015)OBJECTIVES: Sorafenib is the first product approved for treatment of RAI refractory locally advanced/metastatic DTC patients. This study was conducted in order to analyze cost-effectiveness of sorafenib for treatment of ... -
The current status of radiotherapy in the definitive treatment of lung cancer in a developing country: Turkey
(Elsevier Science, 2017)Background: To investigate the current status of radiotherapy (RT) trends in the definitive treatment of lung cancer in Turkey. Methods: A questionnaire consisting of 46 questions about the technical facilities, and ... -
Early detection of mononeuritis multiplex & diagnosis of systemic diseases thru electrophysiological work out with polyneuropathy as preceeding symptom
(Elsevier Science, 2015)Background: Mononeuritis multiplex (MNM) is a nervous system disorder that involves damage to at least two separate peripheral nerves. It is a syndrome not a disease, caused by certain systemic diseases like diabetes, ... -
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
(Elsevier Science, 2019)Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ...